The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Subgroup analysis in RE-MIND2, an observational, retrospective cohort study of tafasitamab plus lenalidomide versus systemic therapies in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
 
Grzegorz S. Nowakowski
Consulting or Advisory Role - Bantam Pharmaceutical; Celgene (Inst); Debiopharm Group; Genentech (Inst); Karyopharm Therapeutics; Kite/Gilead; kymera; MorphoSys (Inst); Ryvu Therapeutics; Selvita; TG Therapeutics
Research Funding - Celgene (Inst); MorphoSys (Inst); NanoString Technologies (Inst)
 
Dok Hyun Yoon
Honoraria - Amgen; Celgene; Celltrion; Janssen; Kirin Pharmaceuticals; Roche; Samyang; Takeda
Consulting or Advisory Role - ABclonal; Amgen; Celgene; GC Pharma; Janssen; Novartis; Roche
Research Funding - ABclonal; Amgen; Boryung; Eutilex; Genmab; Janssen Oncology; Roche/Genentech; Samyang
 
Erel Joffe
Consulting or Advisory Role - AstraZeneca; Epizyme
Research Funding - Amgen; BeiGene; Curis; Janssen; MorphoSys; Viracta Therapeutics
 
Pier Luigi Zinzani
Consulting or Advisory Role - ADC Therapeutics; BeiGene; Bristol-Myers Squibb; Celltrion; EUSA Pharma; Gilead Sciences; Incyte; Janssen-Cilag; Kyowa Hakko Kirin; MSD; Novartis; Roche; Sandoz; Secura BIO; SERVIER; Takeda; TG Therapeutics
Speakers' Bureau - EUSA Pharma; MSD; Novartis
 
Lorenzo Sabatelli
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Eva E. Waltl
Employment - MorphoSys
Research Funding - MorphoSys
 
Carmelita G. Alvero
Employment - MorphoSys
Stock and Other Ownership Interests - MorphoSys
Research Funding - MorphoSys
Travel, Accommodations, Expenses - MorphoSys
 
Georg Hess
Honoraria - Abbvie; AstraZeneca; BeiGene; EUSA Pharma; Genmab; Gilead Sciences; Incyte; Janssen; Novartis
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; EUSA Pharma; Genmab; Gilead Sciences; Incyte; Janssen; Novartis
Research Funding - Abbvie; Celgene; Gilead Sciences; Incyte; Janssen
Travel, Accommodations, Expenses - Janssen
 
Peter A. Riedell
Honoraria - Novartis
Consulting or Advisory Role - Bayer; BeiGene; Bristol-Myers Squibb/Celgene; Karyopharm Therapeutics; Kite, a Gilead company; Novartis; Takeda; Verastem
Speakers' Bureau - Bayer; Kite, a Gilead company
Research Funding - Bristol-Myers Squibb/Celgene; Calibr; Kite, a Gilead company; MorphoSys; Novartis
 
Kibum Kim
Research Funding - AstraZeneca; GRAIL; MorphoSys; Myriad Genetics; Pacira Pharmaceuticals
 
Diana Brixner
Consulting or Advisory Role - Haymarket; Millcreek Outcomes Group; Otsuka; Sage Therapeutics; Value Demonstration
 
Gilles A. Salles
Stock and Other Ownership Interests - Owkin
Honoraria - Abbvie; Bayer; Regeneron
Consulting or Advisory Role - Abbvie; BeiGene; BMS; Debiopharm Group; Epizyme; Genmab; incyte; Incyte; Ipsen; Janssen; Kite/Gilead; Loxo/Lilly; Miltenyi Biotec; Molecular Partners; morphosys; Nordic Nanovector; Novartis; RAPT Therapeutics; Roche/Genentech; Takeda; Velosbio